Axol Bioscience introduces CiPA-validated human stem cell-derived ventricular cardiomyocytes to help improve drug discovery
via The Scientist RSS https://ift.tt/kIr9oEy Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation. Using this assay, the cells were shown to be suitable for measuring cardiotoxicity, offering scientists a robust cardiac model for drug discovery and screening. https://ift.tt/fOjB64I August 02, 2022 at 10:54PM